表皮生长因子受体（EGFR）Leu792位点的新型突变可能与晚期非小细胞肺癌对奥希替尼的获得性耐药相关。 - Suppr

Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib in Advanced NSCLC.

作者信息

Chen Kai, Zhou Fei, Shen Wenxiang, Jiang Tao, Wu Xue, Tong Xiaoling, Shao Yang W, Qin Songbing, Zhou Caicun

机构信息

Department of Medical Oncology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People's Republic of China.

Department of Oncology, Shanghai Pulmonary Hospital, Cancer Institute of Tongji University Medical School, Shanghai, People's Republic of China.

出版信息

J Thorac Oncol. 2017 Jun;12(6):e65-e68. doi: 10.1016/j.jtho.2016.12.024. Epub 2017 Jan 16.

DOI:10.1016/j.jtho.2016.12.024

PMID:28093244

Abstract

摘要

相似文献

Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib in Advanced NSCLC.表皮生长因子受体（EGFR）Leu792位点的新型突变可能与晚期非小细胞肺癌对奥希替尼的获得性耐药相关。

J Thorac Oncol. 2017 Jun;12(6):e65-e68. doi: 10.1016/j.jtho.2016.12.024. Epub 2017 Jan 16.

Treatment of a NSCLC patient with osimertinib based on the detection of the EGFR T790M resistance mutation in cerebrospinal fluid.基于脑脊液中EGFR T790M耐药突变的检测，用奥希替尼治疗一名非小细胞肺癌患者。

Lung Cancer. 2017 Dec;114:111-112. doi: 10.1016/j.lungcan.2017.10.010. Epub 2017 Oct 28.

Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC.连续液体活检揭示了EGFR驱动基因突变的动态变化，并表明EGFR扩增是NSCLC中对奥希替尼耐药的一种新机制。

Lung Cancer. 2017 Jun;108:238-241. doi: 10.1016/j.lungcan.2017.04.004. Epub 2017 Apr 10.

NICE approves osimertinib for advanced lung cancer.英国国家卫生与临床优化研究所批准奥希替尼用于治疗晚期肺癌。

Lancet Respir Med. 2016 Dec;4(12):954. doi: 10.1016/S2213-2600(16)30368-X. Epub 2016 Nov 1.

Osimertinib (AZD9291) and CNS Response in Two Radiotherapy-Naïve Patients with EGFR-Mutant and T790M-Positive Advanced Non-Small Cell Lung Cancer.奥希替尼（AZD9291）与两名未经放疗的EGFR突变且T790M阳性的晚期非小细胞肺癌患者的中枢神经系统反应

Clin Drug Investig. 2016 Aug;36(8):683-6. doi: 10.1007/s40261-016-0411-1.

Osimertinib effective in EGFR T790M-positive lung cancer.奥希替尼对EGFR T790M阳性肺癌有效。

Lancet Oncol. 2017 Jan;18(1):e9. doi: 10.1016/S1470-2045(16)30654-4. Epub 2016 Dec 16.

Emerging EML4-ALK Variant 5 as a Concurrent Resistance Mechanism to Osimertinib in a Patient With EGFR E19del/T790M NSCLC.新型EML4-ALK变异体5作为EGFR E19del/T790M非小细胞肺癌患者对奥希替尼的同时性耐药机制

Clin Lung Cancer. 2020 Nov;21(6):562-567. doi: 10.1016/j.cllc.2020.05.009. Epub 2020 May 16.

Uncommon EGFR G724S mutations arise in non-small-cell lung cancer patients with acquired resistance to first-generation EGFR-TKIs.罕见的表皮生长因子受体（EGFR）G724S突变出现在对第一代EGFR酪氨酸激酶抑制剂产生获得性耐药的非小细胞肺癌患者中。

Lung Cancer. 2018 Apr;118:173-175. doi: 10.1016/j.lungcan.2018.02.016. Epub 2018 Mar 2.

Osimertinib in Stage III -Mutated NSCLC - Game, Set, Match.奥希替尼用于Ⅲ期表皮生长因子受体（EGFR）突变型非小细胞肺癌——赛点、决胜局、比赛结束。（注：这里意译了，因为原英文标题比较简洁且有一定隐喻性，直译为“奥希替尼用于Ⅲ期EGFR突变型非小细胞肺癌——比赛、盘、赛点”不太符合中文表达习惯，所以结合语境意译得更通顺些，你可根据实际需求调整。严格按要求不添加解释说明的话，就按上面的译文即可。）

N Engl J Med. 2024 Aug 15;391(7):652-654. doi: 10.1056/NEJMe2406495.

L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC.L718Q突变作为EGFR突变型非小细胞肺癌对AZD9291获得性耐药的新机制

J Thorac Oncol. 2016 Oct;11(10):e121-3. doi: 10.1016/j.jtho.2016.05.019. Epub 2016 May 31.

引用本文的文献

Personalized care for patients with EGFR-mutant nonsmall cell lung cancer: Navigating early to advanced disease management.表皮生长因子受体（EGFR）突变型非小细胞肺癌患者的个性化护理：从早期到晚期疾病管理的全程指引

CA Cancer J Clin. 2025 Sep-Oct;75(5):387-409. doi: 10.3322/caac.70024. Epub 2025 Jul 17.

Strategies Beyond 3rd EGFR-TKI Acquired Resistance: Opportunities and Challenges.第三代表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）获得性耐药后的策略：机遇与挑战

Cancer Med. 2025 May;14(9):e70921. doi: 10.1002/cam4.70921.

A rare epidermal growth factor receptor T790M/cis-C797S/L718Q compound mutation in a lung adenocarcinoma patient who did not derive any benefit from combination therapy with afatinib and bevacizumab.一名肺腺癌患者中罕见的表皮生长因子受体T790M/cis-C797S/L718Q复合突变，该患者未从阿法替尼和贝伐单抗联合治疗中获得任何益处。

SAGE Open Med Case Rep. 2025 Feb 17;13:2050313X251319381. doi: 10.1177/2050313X251319381. eCollection 2025.

Optimizing Osimertinib for NSCLC: Targeting Resistance and Exploring Combination Therapeutics.优化奥希替尼用于非小细胞肺癌的治疗：靶向耐药性并探索联合疗法。

Cancers (Basel). 2025 Jan 29;17(3):459. doi: 10.3390/cancers17030459.

Tumor-associated macrophages mediate resistance of EGFR-TKIs in non-small cell lung cancer: mechanisms and prospects.肿瘤相关巨噬细胞介导非小细胞肺癌中 EGFR-TKIs 的耐药性：机制与展望。

Front Immunol. 2023 Aug 15;14:1209947. doi: 10.3389/fimmu.2023.1209947. eCollection 2023.

Osimertinib Resistance: Molecular Mechanisms and Emerging Treatment Options.奥希替尼耐药：分子机制与新出现的治疗选择

Cancers (Basel). 2023 Jan 30;15(3):841. doi: 10.3390/cancers15030841.

Resistor: An algorithm for predicting resistance mutations via Pareto optimization over multistate protein design and mutational signatures.电阻器：一种通过多态蛋白质设计和突变特征的 Pareto 优化来预测耐药突变的算法。

Cell Syst. 2022 Oct 19;13(10):830-843.e3. doi: 10.1016/j.cels.2022.09.003.

L718Q/V mutation in exon 18 of EGFR mediates resistance to osimertinib: clinical features and treatment.表皮生长因子受体（EGFR）第18外显子中的L718Q/V突变介导对奥希替尼的耐药性：临床特征与治疗

Discov Oncol. 2022 Aug 9;13(1):72. doi: 10.1007/s12672-022-00537-7.

Blockade of STAT3/IL-4 overcomes EGFR T790M-cis-L792F-induced resistance to osimertinib via suppressing M2 macrophages polarization.阻断 STAT3/IL-4 可通过抑制 M2 巨噬细胞极化克服 EGFR T790M-cis-L792F 诱导的奥希替尼耐药。

EBioMedicine. 2022 Sep;83:104200. doi: 10.1016/j.ebiom.2022.104200. Epub 2022 Aug 3.

Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.第三代表皮生长因子受体（EGFR）和间变性淋巴瘤激酶（ALK）抑制剂：耐药机制与处理

Nat Rev Clin Oncol. 2022 Aug;19(8):499-514. doi: 10.1038/s41571-022-00639-9. Epub 2022 May 9.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib in Advanced NSCLC.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献